http://www.newswire.ca/en/releases/archive/January2007/16/c6014.html
January 16, 2007 (CNW Group)- Victhom Human Bionics Inc. (TSX: VHB) announces today that it received approval from the Ethics Review Board of the rehabilitation center where its clinical trial on gait disorders will be held. The Company received its Investigational Testing Authorization in December 2006 from Health Canada. The Neurostep(TM) is designed to treat, through neuromodulation, gait disorders (e.g., foot drop) secondary to a lesion of the central nervous system caused by conditions such as stroke or multiple sclerosis. Over one million patients in the U.S. and in Europe could benefit from this product…